About Age-related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is an eye condition that affects the macula, a small area at the centre of the retina responsible for sharp, detailed vision. AMD becomes more common with age and can affect one or both eyes.
AMD can cause blurred, distorted or reduced central vision, making everyday activities such as reading, driving and recognising faces more difficult. Straight lines may appear wavy, and in advanced cases, dark or blurred areas may develop in the centre of vision. Peripheral (side) vision usually remains unaffected.
In its early stages, AMD may develop without noticeable symptoms, making regular eye examinations important for early detection and monitoring.
Types of Age-related Macular Degeneration (AMD)
AMD has two main types: dry and wet. They differ in how they develop, progress and affect vision.
- Dry AMD: Dry AMD is the most common type, and it is associated with the build-up of small deposits called drusen beneath the retina and gradual changes to the cells of the macula. Dry AMD can progress through early, intermediate and advanced stages, although not everyone will develop advanced disease. The advanced stage of dry AMD is known as geographic atrophy, in which cells in the macula progressively deteriorate, potentially causing permanent loss of central vision. Some people with dry AMD may also develop wet AMD, which can occur at any stage.
- Wet AMD: Wet AMD is less common but can progress much more rapidly. It occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, damaging the macula. Without prompt treatment, wet AMD can lead to scarring and permanent loss of central vision.
Causes of AMD
The exact cause of AMD is not fully understood, but ageing is the strongest risk factor. Genetic and lifestyle factors can also influence the likelihood of developing the condition.
People who smoke or have a family history of AMD are at increased risk. High blood pressure and being overweight have also been linked to the condition. However, having one or more of these risk factors does not necessarily mean a person will develop AMD.
Smoking is the most important risk factor that can be changed, and stopping smoking may help reduce the risk of developing AMD or its progression.
Symptoms of AMD
Symptoms can vary depending on the stage of AMD and may be difficult to notice, particularly when one eye is more affected than the other, as the stronger eye can compensate.
Some people may experience difficulty seeing in low light, need brighter lighting for reading or close-up activities, or notice that colours appear less vivid. Reduced contrast sensitivity can also make it harder to distinguish objects from their surroundings.
Some people with significant sight loss from AMD may experience visual hallucinations, such as seeing patterns, shapes or faces that are not there. This may be caused by Charles Bonnet syndrome, a condition associated with sight loss that is not itself a mental health disorder. Anyone experiencing these symptoms should seek medical assessment to rule out other possible causes.
AMD does not usually cause pain or visible changes to the appearance of the eyes. However, any sudden changes in central vision require urgent assessment by an ophthalmologist.
Treatment of Age-related Macular Degeneration (AMD)
AMD treatment depends on the type and stage of the condition, with the aim of preserving vision and slowing disease progression.
Treatment for wet AMD
Wet AMD is usually treated with injections into the eye of medicines known as anti-vascular endothelial growth factor (anti-VEGF) agents. These medicines help control the growth and leakage of abnormal blood vessels beneath the retina, helping to stabilise vision and, in some cases, improve it.
Treatment usually involves a series of injections at regular intervals, with frequency adjusted based on how the eye responds. Many patients require ongoing treatment to keep the condition under control. Regular monitoring lets the ophthalmologist assess treatment effectiveness and decide when further injections are needed.
In selected cases, photodynamic therapy (PDT), a specialised light-activated treatment, may also be considered.
Treatment for dry AMD
There is currently no cure for dry AMD. Management focuses on monitoring the condition, reducing the risk of progression and preserving existing vision. For people with intermediate AMD in one or both eyes, or advanced AMD in one eye, a specific combination of vitamins and minerals known as AREDS2 supplements may help reduce the risk of progression to advanced disease in the affected or fellow eye.
These supplements do not prevent AMD from developing or restore vision that has already been lost. They are not suitable for everyone and should be taken only on an ophthalmologist’s advice.
For patients experiencing significant vision loss, low vision aids and rehabilitation services may help with everyday activities and maintaining independence.